EA200300424A1 - Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов - Google Patents

Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов

Info

Publication number
EA200300424A1
EA200300424A1 EA200300424A EA200300424A EA200300424A1 EA 200300424 A1 EA200300424 A1 EA 200300424A1 EA 200300424 A EA200300424 A EA 200300424A EA 200300424 A EA200300424 A EA 200300424A EA 200300424 A1 EA200300424 A1 EA 200300424A1
Authority
EA
Eurasian Patent Office
Prior art keywords
salts
isothiazole
hemicitrate
hemisuccinate
hydrobromic
Prior art date
Application number
EA200300424A
Other languages
English (en)
Other versions
EA005859B1 (ru
Inventor
Томас Дж. Гант
Гленн Роберт Уильямс
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200300424A1 publication Critical patent/EA200300424A1/ru
Publication of EA005859B1 publication Critical patent/EA005859B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Данное изобретение относится к солянокислой, бромисто-водородной, гемицитратной, ацетатной, паратозилатной, L-тартратной, гемисукцинатной и мезилатной солевым формам амида 3-(4-бром-2,6-дифторбензилокси)-5-[3-(4-пирролидин-1-ил-бутил)уреидо]изотиазол-4-карбоновой кислоты, имеющим следующую формулу I. Данное изобретение также относится к фармацевтическим композициям, содержащим солянокислую, бромисто-водородную, гемицитратную, ацетатную, пара-тозилатную, L-тартратную, гемисукцинатную и мезилатную соли формулы I. Данное изобретение, кроме того, относится к способам лечения гиперпролиферативных заболеваний, таких как рак, у млекопитающих, особенно у людей, при которых вводят указанные выше соли, и к способам получения кристаллических форм указанных выше солей.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200300424A 2000-11-28 2001-11-19 Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов EA005859B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25351300P 2000-11-28 2000-11-28
PCT/IB2001/002193 WO2002044158A1 (en) 2000-11-28 2001-11-19 Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents

Publications (2)

Publication Number Publication Date
EA200300424A1 true EA200300424A1 (ru) 2003-10-30
EA005859B1 EA005859B1 (ru) 2005-06-30

Family

ID=22960587

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300424A EA005859B1 (ru) 2000-11-28 2001-11-19 Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов

Country Status (50)

Country Link
US (1) US6831091B2 (ru)
EP (1) EP1337521B1 (ru)
JP (2) JP2004514714A (ru)
KR (2) KR20030059275A (ru)
CN (1) CN1231474C (ru)
AP (1) AP2001002358A0 (ru)
AR (1) AR031512A1 (ru)
AT (1) ATE340786T1 (ru)
AU (2) AU1420402A (ru)
BG (1) BG107752A (ru)
BR (1) BR0115621A (ru)
CA (1) CA2430065C (ru)
CR (1) CR6963A (ru)
CY (1) CY1106240T1 (ru)
CZ (1) CZ20031315A3 (ru)
DE (1) DE60123461T2 (ru)
DK (1) DK1337521T3 (ru)
DO (1) DOP2001000288A (ru)
EA (1) EA005859B1 (ru)
EC (1) ECSP034628A (ru)
EE (1) EE200300247A (ru)
ES (1) ES2271086T3 (ru)
GE (1) GEP20053652B (ru)
GT (1) GT200100237A (ru)
HK (1) HK1059085A1 (ru)
HN (1) HN2001000268A (ru)
HR (1) HRP20030408A2 (ru)
HU (1) HUP0302553A3 (ru)
IL (1) IL155371A0 (ru)
IS (1) IS6788A (ru)
MA (1) MA26960A1 (ru)
MX (1) MXPA03004714A (ru)
MY (1) MY136686A (ru)
NO (1) NO325187B1 (ru)
NZ (1) NZ525788A (ru)
OA (1) OA12532A (ru)
PA (1) PA8533801A1 (ru)
PE (1) PE20020591A1 (ru)
PL (1) PL362079A1 (ru)
PT (1) PT1337521E (ru)
SI (1) SI1337521T1 (ru)
SK (1) SK5862003A3 (ru)
SV (1) SV2002000748A (ru)
TN (1) TNSN01167A1 (ru)
TW (1) TWI287542B (ru)
UA (1) UA74221C2 (ru)
UY (1) UY27039A1 (ru)
WO (1) WO2002044158A1 (ru)
YU (1) YU36403A (ru)
ZA (1) ZA200303341B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (ru) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Производные изотиазола, способ их получения, фармацевтическая композиция и способ лечения гиперпролиферативного заболевания у млекопитающего
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2000041698A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
WO2004011461A1 (en) * 2002-07-25 2004-02-05 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
RS20050106A (en) * 2002-08-19 2007-11-15 Pfizer Products Inc., Combination therapy for hyperproliferative diseases
DE602004007382T2 (de) 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
DE602004010407T2 (de) 2003-07-23 2008-10-16 Bayer Pharmaceuticals Corp., West Haven Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
MXPA06004647A (es) * 2003-10-27 2006-06-27 Merck & Co Inc Sal antagonista de ccr-2.
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
WO2005102327A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Dosage forms and methods of treatment using vegfr inhibitors
JP2007535565A (ja) 2004-04-30 2007-12-06 バイエル ファーマシューティカルス コーポレーション 癌の治療に有用な置換ピラゾリル尿素誘導体
TW200538104A (en) * 2004-05-17 2005-12-01 Pfizer Prod Inc Phenyl derivatives for the treatment of abnormal cell growth
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN102617513B (zh) 2006-06-16 2015-09-23 H.隆德贝克有限公司 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5-ht3和5-ht1a活性的化合物的1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
MX2010001636A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
WO2011073521A1 (en) 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
JP2013538191A (ja) 2010-07-23 2013-10-10 トラスティーズ オブ ボストン ユニバーシティ 病的血管新生および腫瘍細胞侵襲性の阻害のための治療法としてならびに分子イメージングおよび標的化送達のための抗ＤＥｓｕｐＲ阻害剤
SG10201710928PA (en) * 2013-03-14 2018-02-27 Panoptica Inc Ocular formulations for drug-delivery to the posterior segment of the eye
CN106999476B (zh) * 2014-09-17 2021-05-04 盼光公司 用于药物递送和保护眼睛前段的眼用制剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (ru) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Производные изотиазола, способ их получения, фармацевтическая композиция и способ лечения гиперпролиферативного заболевания у млекопитающего

Also Published As

Publication number Publication date
HRP20030408A2 (en) 2003-08-31
DE60123461T2 (de) 2007-02-15
JP2008056692A (ja) 2008-03-13
TNSN01167A1 (fr) 2005-11-10
NZ525788A (en) 2004-11-26
TWI287542B (en) 2007-10-01
PA8533801A1 (es) 2002-10-31
CY1106240T1 (el) 2011-06-08
MXPA03004714A (es) 2003-08-19
UY27039A1 (es) 2002-07-31
DOP2001000288A (es) 2002-12-15
SK5862003A3 (en) 2004-05-04
IL155371A0 (en) 2003-11-23
AU2002214204B2 (en) 2007-05-24
EE200300247A (et) 2003-10-15
KR20030059275A (ko) 2003-07-07
CA2430065C (en) 2008-05-20
OA12532A (en) 2006-06-02
HUP0302553A3 (en) 2009-03-30
WO2002044158A1 (en) 2002-06-06
DK1337521T3 (da) 2007-01-29
ECSP034628A (es) 2003-07-25
CZ20031315A3 (cs) 2004-04-14
JP2004514714A (ja) 2004-05-20
HUP0302553A2 (hu) 2003-11-28
ES2271086T3 (es) 2007-04-16
JP4971946B2 (ja) 2012-07-11
US20020151573A1 (en) 2002-10-17
MA26960A1 (fr) 2004-12-20
GT200100237A (es) 2002-07-03
NO325187B1 (no) 2008-02-11
NO20032388D0 (no) 2003-05-27
BG107752A (bg) 2004-01-30
AR031512A1 (es) 2003-09-24
AP2001002358A0 (en) 2001-12-31
EP1337521A1 (en) 2003-08-27
BR0115621A (pt) 2003-09-02
KR20050116401A (ko) 2005-12-12
CA2430065A1 (en) 2002-06-06
PL362079A1 (en) 2004-10-18
US6831091B2 (en) 2004-12-14
SV2002000748A (es) 2002-12-02
GEP20053652B (en) 2005-11-10
EA005859B1 (ru) 2005-06-30
ATE340786T1 (de) 2006-10-15
NO20032388L (no) 2003-07-18
EP1337521B1 (en) 2006-09-27
HN2001000268A (es) 2002-01-30
DE60123461D1 (de) 2006-11-09
HK1059085A1 (en) 2004-06-18
CR6963A (es) 2003-11-25
MY136686A (en) 2008-11-28
CN1231474C (zh) 2005-12-14
IS6788A (is) 2003-04-14
UA74221C2 (ru) 2005-11-15
PE20020591A1 (es) 2002-07-06
CN1476439A (zh) 2004-02-18
AU1420402A (en) 2002-06-11
YU36403A (sh) 2006-08-17
PT1337521E (pt) 2006-12-29
SI1337521T1 (sl) 2006-12-31
ZA200303341B (en) 2004-04-30

Similar Documents

Publication Publication Date Title
EA200300424A1 (ru) Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов
EA200500814A1 (ru) Производные пирролопиримидина
EA200200716A1 (ru) Арилконденсированные азаполициклические соединения
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
ATE517882T1 (de) Chinolinderivate
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
DK1678166T3 (da) Proteinkinaseinhibitorer
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
ATE440603T1 (de) 8-hydroxychinolinderivate
MXPA05011150A (es) 2-hidroxi-3-diaminoalcanos de benzamida.
RU2007128080A (ru) Производные пирролидиния в качестве мускариновых рецепторов мз
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
TW200639159A (en) Treatment of pain
TNSN04165A1 (en) Substituted hydroxyethylamines
WO2005056524A3 (en) Therapeutic agents useful for treating pain
HK1079526A1 (en) A novel pyrazine compound and its use in the manufacture of a medicament for treating diseases related to serotonin
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
HUP0301272A2 (hu) 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
TW200716547A (en) Piperidin-4-yl-amide derivatives
ATE469157T1 (de) Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
ATE403426T1 (de) Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen
EA200401301A1 (ru) Полициклические соединения как эффективные антагонисты альфа-2 адренорецептора
EA200901474A1 (ru) Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе
ATE466007T1 (de) 5-substituierte indol-2-carbonsäureamidderivate
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU